Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer

R. Silvestrini, M. G. Daidone, A. Luisi, P. Boracchi, M. Mezzetti, G. Di Fronzo, S. Andreola, B. Salvadori, U. Veronesi

Research output: Contribution to journalArticle

Abstract

Purpose and Methods: We evaluated, in 1,800 patients with node-negative tumors treated with locoregional therapy until relapse, the competitive risks for different types of metastasis by cell proliferation (3H-thymidine labeling index [3H-dT LI]), estrogen receptors (ERs), and progesterone receptors (PgRs), and by the integration of biologic and clinicopathologic information. Results: Hormone receptor status and proliferative activity of the primary tumor were not indicative of contralateral failures. Hormone receptors failed to predict the 8-year incidence of locoregional recurrence, but they were significant indicators of distant metastasis and overall survival. The latter finding was confirmed even in multivariate analysis. Conversely, cell proliferation predicted both locoregional and distant metastases and survival, regardless of patient age, tumor size, and ER and PgR status. Recursive partitioning and amalgamation analysis ascribed to cell proliferation an important prognostic role for locoregional recurrence together with patient age, and for distant metastasis together with patient age and tumor size. Conclusion: Biologic markers, in particular cell proliferation, provide information for the different types of relapse and could complement the predictive role of pathologic staging.

Original languageEnglish
Pages (from-to)697-704
Number of pages8
JournalJournal of Clinical Oncology
Volume13
Issue number3
Publication statusPublished - 1995

Fingerprint

Biological Factors
Cell Proliferation
Breast Neoplasms
Neoplasm Metastasis
Recurrence
Estrogen Receptors
Neoplasms
Hormones
Survival
Progesterone Receptors
Thymidine
Multivariate Analysis
Biomarkers
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Silvestrini, R., Daidone, M. G., Luisi, A., Boracchi, P., Mezzetti, M., Di Fronzo, G., ... Veronesi, U. (1995). Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. Journal of Clinical Oncology, 13(3), 697-704.

Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. / Silvestrini, R.; Daidone, M. G.; Luisi, A.; Boracchi, P.; Mezzetti, M.; Di Fronzo, G.; Andreola, S.; Salvadori, B.; Veronesi, U.

In: Journal of Clinical Oncology, Vol. 13, No. 3, 1995, p. 697-704.

Research output: Contribution to journalArticle

Silvestrini, R, Daidone, MG, Luisi, A, Boracchi, P, Mezzetti, M, Di Fronzo, G, Andreola, S, Salvadori, B & Veronesi, U 1995, 'Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer', Journal of Clinical Oncology, vol. 13, no. 3, pp. 697-704.
Silvestrini, R. ; Daidone, M. G. ; Luisi, A. ; Boracchi, P. ; Mezzetti, M. ; Di Fronzo, G. ; Andreola, S. ; Salvadori, B. ; Veronesi, U. / Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 3. pp. 697-704.
@article{230c9e06b57542a78945758f6a3bfdab,
title = "Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer",
abstract = "Purpose and Methods: We evaluated, in 1,800 patients with node-negative tumors treated with locoregional therapy until relapse, the competitive risks for different types of metastasis by cell proliferation (3H-thymidine labeling index [3H-dT LI]), estrogen receptors (ERs), and progesterone receptors (PgRs), and by the integration of biologic and clinicopathologic information. Results: Hormone receptor status and proliferative activity of the primary tumor were not indicative of contralateral failures. Hormone receptors failed to predict the 8-year incidence of locoregional recurrence, but they were significant indicators of distant metastasis and overall survival. The latter finding was confirmed even in multivariate analysis. Conversely, cell proliferation predicted both locoregional and distant metastases and survival, regardless of patient age, tumor size, and ER and PgR status. Recursive partitioning and amalgamation analysis ascribed to cell proliferation an important prognostic role for locoregional recurrence together with patient age, and for distant metastasis together with patient age and tumor size. Conclusion: Biologic markers, in particular cell proliferation, provide information for the different types of relapse and could complement the predictive role of pathologic staging.",
author = "R. Silvestrini and Daidone, {M. G.} and A. Luisi and P. Boracchi and M. Mezzetti and {Di Fronzo}, G. and S. Andreola and B. Salvadori and U. Veronesi",
year = "1995",
language = "English",
volume = "13",
pages = "697--704",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer

AU - Silvestrini, R.

AU - Daidone, M. G.

AU - Luisi, A.

AU - Boracchi, P.

AU - Mezzetti, M.

AU - Di Fronzo, G.

AU - Andreola, S.

AU - Salvadori, B.

AU - Veronesi, U.

PY - 1995

Y1 - 1995

N2 - Purpose and Methods: We evaluated, in 1,800 patients with node-negative tumors treated with locoregional therapy until relapse, the competitive risks for different types of metastasis by cell proliferation (3H-thymidine labeling index [3H-dT LI]), estrogen receptors (ERs), and progesterone receptors (PgRs), and by the integration of biologic and clinicopathologic information. Results: Hormone receptor status and proliferative activity of the primary tumor were not indicative of contralateral failures. Hormone receptors failed to predict the 8-year incidence of locoregional recurrence, but they were significant indicators of distant metastasis and overall survival. The latter finding was confirmed even in multivariate analysis. Conversely, cell proliferation predicted both locoregional and distant metastases and survival, regardless of patient age, tumor size, and ER and PgR status. Recursive partitioning and amalgamation analysis ascribed to cell proliferation an important prognostic role for locoregional recurrence together with patient age, and for distant metastasis together with patient age and tumor size. Conclusion: Biologic markers, in particular cell proliferation, provide information for the different types of relapse and could complement the predictive role of pathologic staging.

AB - Purpose and Methods: We evaluated, in 1,800 patients with node-negative tumors treated with locoregional therapy until relapse, the competitive risks for different types of metastasis by cell proliferation (3H-thymidine labeling index [3H-dT LI]), estrogen receptors (ERs), and progesterone receptors (PgRs), and by the integration of biologic and clinicopathologic information. Results: Hormone receptor status and proliferative activity of the primary tumor were not indicative of contralateral failures. Hormone receptors failed to predict the 8-year incidence of locoregional recurrence, but they were significant indicators of distant metastasis and overall survival. The latter finding was confirmed even in multivariate analysis. Conversely, cell proliferation predicted both locoregional and distant metastases and survival, regardless of patient age, tumor size, and ER and PgR status. Recursive partitioning and amalgamation analysis ascribed to cell proliferation an important prognostic role for locoregional recurrence together with patient age, and for distant metastasis together with patient age and tumor size. Conclusion: Biologic markers, in particular cell proliferation, provide information for the different types of relapse and could complement the predictive role of pathologic staging.

UR - http://www.scopus.com/inward/record.url?scp=0028907257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028907257&partnerID=8YFLogxK

M3 - Article

C2 - 7884430

AN - SCOPUS:0028907257

VL - 13

SP - 697

EP - 704

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -